Beliefs about current practice, facilitators and barriers to the pharmaceutical management of LVSD and HFpEF
| Management issue | GP | Cardiologist | General physician | HF nurse | All respondents |
|---|---|---|---|---|---|
| N=251 | N=103 | N=54 | N=78 | N=494 | |
| Role in management of LVSD | 203 (80.9%) | 100 (97.1%) | 44 (81.5%) | 74 (94.9%) | 421 (85.2%) |
| Role in management of HFpEF | 69 (27.5%) | 87 (84.5%) | 29 (53.7%) | 51 (65.4%) | 236 (47.8%) |
| Initiate medication for LVSD | 202 (80.5%) | 102 (99.0%) | 50 (92.6%) | 73 (93.6%) | 427 (86.4%) |
| Titrate medication for LVSD | 225 (89.6%) | 101 (98.1%) | 50 (92.6%) | 77 (98.7%) | 453 (91.7%) |
| Initiate diuretics for LVSD | 193 (76.9%) | 97 (94.2%) | 46 (85.2%) | 70 (89.7%) | 406 (82.2%) |
| Titrate diuretics for LVSD | 165 (65.7%) | 61 (59.2%) | 30 (55.6%) | 70 (89.7%) | 326 (66.0%) |
| Initiate ACEi for LVSD | 196 (78.1%) | 101 (98.1%) | 49 (90.7%) | 71 (91.0%) | 417 (84.4%) |
| Titrate ACEi for LVSD | 204 (81.3%) | 92 (89.3%) | 33 (61.1%) | 76 (97.4%) | 405 (82.0%) |
| Initiate ARB for LVSD | 128 (51.0%) | 80 (77.7%) | 21 (38.9%) | 64 (82.1%) | 293 (59.3%) |
| Titrate ARB for LVSD | 113 (45.0%) | 65 (63.1%) | 11 (20.4%) | 73 (93.6%) | 262 (53.0%) |
| Initiate β-blockers for LVSD | 155 (61.8%) | 101 (98.1%) | 41 (75.9%) | 69 (88.5%) | 366 (74.1%) |
| Titrate β-blockers for LVSD | 181 (72.1%) | 91 (88.3%) | 30 (55.6%) | 76 (97.4%) | 378 (76.5%) |
| Initiate spironolactone for LVSD | 95 (37.8%) | 98 (95.1%) | 40 (74.1%) | 67 (85.9%) | 300 (60.7%) |
| Titrate spironolactone for LVSD | 79 (31.5%) | 48 (46.6%) | 19 (35.2%) | 63 (80.8%) | 209 (42.3%) |
| Initiate digoxin for LVSD | 55 (21.9%) | 63 (61.2%) | 24 (44.4%) | 41 (52.6%) | 183 (37.0%) |
| Titrate digoxin for LVSD | 47 (18.7%) | 29 (28.2%) | 10 (18.5%) | 39 (50.0%) | 125 (25.3%) |
ACEi, ACE-inhibition; ARB, angiotensin receptor blockers; GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.